Prevalence of Diagnosed Opioid Abuse and its Economic Burden in the Veterans Health Administration
- 30 June 2013
- journal article
- research article
- Published by Wiley in Pain Practice
- Vol. 14 (5), 437-445
- https://doi.org/10.1111/papr.12097
Abstract
Objective Evaluate prevalence and risk-adjusted healthcare costs of diagnosed opioid abuse in the national Veterans Health Administration (VHA). Costs were compared between patients with and without diagnosed opioid abuse. Design Medical and pharmacy claims analysis of VHA data (10/01/2006 to 09/30/2010) were retrospectively analyzed. Prevalence was calculated as the percent of patients with diagnosed opioid abuse for the entire VHA membership and those with noncancer pain diagnoses, compared between patients prescribed opioids prior to abuse diagnosis and those not prescribed opioids through the VHA system. Healthcare utilization and costs were estimated using matching techniques and generalized linear models to control for clinical and demographic differences between patients with and without diagnosed opioid abuse. Separate comparisons were made (with diagnosed abuse vs. without) for each cohort: patients with/without opioid prescriptions. Results Five-year diagnosed opioid abuse was 1.11%. Among patients prescribed opioids, 5-year abuse prevalence was 3.04%. Pain patients prescribed opioids had the highest abuse rate at 3.26%. Adjusted annual healthcare costs for diagnosed opioid abuse patients were higher than for those without diagnosed abuse, (prescribed opioids overall healthcare costs: $28,882, with diagnosed abuse vs. $13,605 for those without; not prescribed opioids: $25,197 vs. $6350, P-value< 0.0001; opioid-specific healthcare costs for patients prescribed opioids: $8956 vs. $218; patients not prescribed opioids: $8733 vs. $20). Conclusions Diagnosed opioid abuse prevalence is almost 7-fold higher in the veteran's administration population than in commercial health plans and translates to a significant economic burden. Appropriate interventions should be considered to prevent and reduce opioid abuse.Keywords
Funding Information
- Pfizer Inc., New York, NY
This publication has 9 references indexed in Scilit:
- Association of Mental Health Disorders With Prescription Opioids and High-Risk Opioid Use in US Veterans of Iraq and AfghanistanJAMA, 2012
- Assessment, stratification, and monitoring of the risk for prescription opioid misuse and abuse in the primary care settingJournal of Opioid Management, 2011
- Societal Costs of Prescription Opioid Abuse, Dependence, and Misuse in the United StatesPain Medicine, 2011
- Costs of Opioid Abuse and Misuse Determined From a Medicaid DatabaseJournal of Pain & Palliative Care Pharmacotherapy, 2010
- Economic Burden of Prescription Opioid Misuse and AbuseJournal of Managed Care Pharmacy, 2009
- Risk factors for clinically recognized opioid abuse and dependence among veterans using opioids for chronic non-cancer painPain, 2007
- Opioid Prescriptions SoarJAMA, 2007
- How to measure comorbiditya critical review of available methodsJournal of Clinical Epidemiology, 2003
- Adapting a clinical comorbidity index for use with ICD-9-CM administrative databasesJournal of Clinical Epidemiology, 1992